Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study
- 25 September 2006
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 16 (4) , 385-392
- https://doi.org/10.1002/pds.1297
Abstract
Background There is considerable evidence that statins can reduce cardiovascular events. Currently high‐risk patients are treated to a target cholesterol concentration. An alternative prescribing strategy (the ‘fire‐and‐forget’ approach) would instead deploy low‐dose statins more widely. It has been suggested that for the same cost this approach might prevent more cardiovascular events. We have compared the treat‐to‐target and fire‐and‐forget statin prescribing strategies with respect to adherence and cardiovascular outcomes. Methods We used a population‐based record‐linkage database containing several data sets linked by a unique patient identifier. We identified two cohorts of patients. Patients in the treat‐to‐target cohort were prescribed a statin, and subsequent measurement of their cholesterol was followed by upward titration of their statin dose if necessary. Patients in the fire‐and‐forget cohort were prescribed a statin, but no further cholesterol measurement was observed during the follow‐up period. Findings Adherence to statin treatment in patients treated to target was significantly better than in patients treated on a fire‐and‐forget basis (adjusted odds ratio 2.51, 95%CI 2.26–2.78). We found a lower cardiovascular disease (CVD) event rate in patients treated to target than in fire‐and‐forget patients (hazard ratio of CVD or cardiovascular death 0.41 (0.35–0.48) even after adjustment was made for adherence and baseline CVD risk). Interpretation Our findings suggest that adherence to statins is worse in patients treated on a fire‐and‐forget basis than in patients treated to a target cholesterol concentration, and that this prescribing strategy is associated with worse cardiovascular outcomes. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 20 references indexed in Scilit:
- Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IVJournal of Human Hypertension, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR * Trial)Published by Elsevier ,2003
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugsThe Lancet, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Inhalation of levomepromazine in severe acute asthmaThe Lancet, 1994